Stock Financial Ratios, Dividends, Split History

IMKTA / Ingles Markets, Incorporated financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)425.95
Enterprise Value ($M)1,301.54
Book Value ($M)558.99
Book Value / Share39.57
Price / Book0.75
NCAV ($M)-761.60
NCAV / Share-53.91
Price / NCAV-0.55
Share Statistics
Common Shares Outstanding2 6,145,732
Common Shares Outstanding 14,114,044
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.04
Return on Assets (ROA)0.03
Return on Equity (ROE)0.11
Balance Sheet (mrq) ($M)
Quick Ratio0.38
Current Ratio1.81
Income Statement (mra) ($M)
Sales Revenue Goods Net4,002,699,727.00
Operating Income127.91
Net Income53.87
Cash Flow Statement (mra) ($M)
Cash From Operations156.34
Cash from Investing-125.36
Cash from Financing156.34
Identifiers and Descriptors
Central Index Key (CIK)50493
Related CUSIPS
457030954 457030904
Industry Groups
SIC 5411 - Grocery Stores

Split History

Stock splits are used by Ingles Markets, Incorporated to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Is Ingles Markets (IMKTA) a Great Stock for Value Investors?

2018-06-15 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. (5-0)

5 Stocks to Snap Up From Favorably-Ranked Retail Industries

2018-04-06 zacks
The investment scenario has turned topsy-turvy of late, with no respite in sight. Tensions between two of the world’s biggest economies aggravated after Trump asked U.S. Trade Representatives to locate options to impose another $100 billion in tariffs on China products. Although the effective date of tariff implementation has not been decided yet, a fresh bout of uncertainty is about to spook the Wall Street. (23-0)

Ingles Markets: Why You Shouldn't Buy This Stock

2018-04-02 seekingalpha
Ingles Markets increased comparable store sales by 1.5% during 2017, but other financial metrics are showing weakness. (1-0) featured highlights include: Momo, Solaris Oilfield, Facebook, MCBC and Nintendo

2018-03-28 zacks
Chicago, IL – March 28, 2018 - Stocks in this week’s article Momo Inc. (MOMO - Free Report) , Solaris Oilfield Infrastructure, Inc. (SOI - Free Report) , Facebook, Inc. (FB - Free Report) , MCBC Holdings, Inc. (MCFT - Free Report) and Nintendo Co., Ltd. (NTDOY - Free Report) . (76-0)

Zacks Investment Ideas feature highlights: Chevron, Exxon, Valero, Halliburton and Flotek

2018-03-28 zacks
Chicago, IL – March 28, 2018 – Today, Zacks Investment Ideas feature highlights Features: Chevron (CVX - Free Report) , Exxon Mobile (XOM - Free Report) , Valero (VLO - Free Report) , Halliburton (HAL - Free Report) and Flotek (FTK - Free Report) . (28-0)

CUSIP: 457030104